RAF/RAS oncogenes and mismatch-repair status
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Genes of the RAF family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Activating mutations in one RAF gene, BRAF, have been found in a high proportion of melanomas and in a small fraction of other cancers. Here we show that BRAF mutations in colorectal cancers occur only in tumours that do not carry mutations in a RAS gene known as KRAS, and that BRAF mutation is linked to the proficiency of these tumours in repairing mismatched bases in DNA. Our results not only provide genetic support for the idea that mutations in BRAF and KRAS exert equivalent effects in tumorigenesis, but also emphasize the role of repair processes in establishing the mutation spectra that underpin human cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [160]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Self-citationStabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines
Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., & Polakis, P. (1997) · Science · doi:10.1126/science.275.5307.1790 · Cited by 1,223
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks, A. B., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · PubMed · Cited by 1,008
Self-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456
Mechanisms underlying losses of heterozygosity in human colorectal cancers
Thiagalingam, S., Laken, S., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051625398 · Cited by 228
Self-citationPrevalence of somatic alterations in the colorectal cancer cell genome
Wang, T.-L., Rago, C., Silliman, N., Ptak, J., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261714699 · Cited by 177
Self-citationOncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors
Storm, S. M., & Rapp, U. R. (1993) · Toxicology Letters · doi:10.1016/0378-4274(93)90056-4 · Cited by 53
Research works printed but not linked: 2
- Sparks, A. B., Morin, P. J., Vogelstein, B. & Kinzler, K. W. Cancer Res. 58, 1130–1134 (1998).
- Markowitz, S. J. Clin. Oncol. 18 (suppl.), 75–80 (2000).
Cited by
Items 201–300 of 999
Mackenzie, R., Kommoss, S., Winterhoff, B. J. N., Kipp, B. R., García, J. J., Voss, J. S., Halling, K. C., Karnezis, A. N., Senz, J., Yang, W., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1421-8 · Cited by 172
“Based on our previous data suggesting a near-mutual exclusivity of RAS-pathway alterations in MC as well as numerous similar examples in the literature [42–44], we expected KRAS mutations would be restricted to regions lacking ERBB2 positivity.”
ResultTGF-β Signaling Alterations and Colon Cancer
Bellam, N., & Pasche, B. (2010) · Cancer treatment and research · doi:10.1007/978-1-4419-6033-7_5 · Cited by 158
Biomarkers in colorectal cancer: Current clinical utility and future perspectives
Vacante, M., Borzì, A. M., Basile, F., & Biondi, A. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i15.869 · Cited by 169
Payne, S. R., Church, T. R., Wandell, M., Rösch, T., Osborn, N. K., Snover, D. C., Day, R. W., Ransohoff, D. F., & Rex, D. K. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.11.034 · Cited by 149
Daniels, M., Lurkin, I., Pauli, R., Erbstößer, E., Hildebrandt, U., Hellwig, K., Zschille, U., Lüders, P., Krüger, G., Knolle, J., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.07.029 · Cited by 156
Zhu, F., Zykova, T. A., Kang, B. S., Wang, Z., Ebeling, M. C., Abe, Y., Ma, W., Bode, A. M., & Dong, Z. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.048 · Cited by 157
The Ras Effector RASSF2 Is a Novel Tumor-Suppressor Gene in Human Colorectal Cancer
Akino, K., Toyota, M., Suzuki, H., Mita, H., Sasaki, Y., Ohe-Toyota, M., Issa, J. J., Hinoda, Y., Imai, K., & Tokino, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.051 · Cited by 148
Colorectal Carcinogenesis: MSI‐H Versus MSI‐L
Pawlik, T. M., Raut, C. P., & Rodríguez-Bigas, M. A. (2004) · Disease Markers · doi:10.1155/2004/368680 · Cited by 177
“done exclusively to the sporadic MSI-H subset [72, 73].”
BackgroundEisenmann, K. M., VanBrocklin, M. W., Staffend, N. A., Kitchen, S. M., & Koo, H.-M. (2003) · PubMed · Cited by 168
Oliveira, C. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh238 · Cited by 144
“KRAS another member of this signalling pathway is mutated in 20% of sporadic MSI-H and 35% of MSS CRCs negative for the BRAF mutation (16,20,21,24,27,28).”
BackgroundCarragher, L. A. S., Snell, K. R., Giblett, S. M., Aldridge, V. S. S., Patel, B., Cook, S. J., Winton, D. J., Marais, R., & Pritchard, C. A. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000099 · Cited by 144
“%) with CIMP-H, MMRdeficient CRCs that arise by MLH1 epigenetic inactivation (Deng et al, 2004; Rajagopalan et al, 2002; Wang et al, 2003; Weisenberger et al, 2006).”
Morkel, M., Riemer, P., Bläker, H., & Sers, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4750 · Cited by 144
“BRAF-mutant CRCs are also characterized by mismatch-repair deficiency, high levels of microsatellite instability (MSI-H) and very high overall mutation rates (>12 mutations per 106 nucleotides) [22].”
BackgroundRational bases for the development of EGFR inhibitors for cancer treatment
Bianco, R., Gelardi, T., Damiano, V., Ciardiello, F., & Tortora, G. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.05.008 · Cited by 158
Detection of BRAF V600E Mutation in Colorectal Cancer
Benlloch, S., Payá, A., Alenda, C., Bessa, X., Andreu, M. G., Jover, R., Castells, A., Llor, X., Aranda, I., & Massutí, B. (2006) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.060070 · Cited by 144
Tokumaru, Y., Yamashita, K., Osada, M., Nomoto, S., Sun, D., Xiao, Y., Hoque, M. O., Westra, W. H., Califano, J. A., & Sidransky, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0993 · Cited by 142
Xing, M., Cohen, Y., Mambo, E., Tallini, G., Udelsman, R., Ladenson, P. W., & Sidransky, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3242 · Cited by 143
“Ras mutations and BRAF mutations are also mutually exclusive in various neoplasms, including colorectal carcinomas (30), colorectal polyps and adenomas (31), melanomas (32), and ovarian carcinomas (33), as well as thyroid cancers (4).”
BackgroundMolecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges
Shih, I.-M., & Kurman, R. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0755 · Cited by 142
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms
Wu, P., & Park, J. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.023 · Cited by 156
Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer
Sullivan, B. A., Noujaim, M. G., & Roper, J. (2022) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2021.12.001 · Cited by 175
Tanaka, H., Deng, G., Matsuzaki, K., Kakar, S., Kim, G., Miura, S., Sleisenger, M. H., & Kim, Y. S. (2005) · International Journal of Cancer · doi:10.1002/ijc.21701 · Cited by 141
Participation of the Elderly Population in Clinical Trials: Barriers and Solutions
Denson, A. C., & Mahipal, A. (2014) · Cancer Control · doi:10.1177/107327481402100305 · Cited by 138
BRAF and KRAS mutations in stomach cancer
Lee, S. H., Lee, J. W., Soung, Y. H., Kim, H. S., Park, W. S., Kim, S. Y., Lee, J., Park, J. Y., Cho, Y. G., Kim, C. J., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206749 · Cited by 135
“…that encode the kinase domains in Gloop and the activation segment of BRAF, respectively (Brose et al., 2002; Davies et al., 2002; Naoki et al., 2002; Pollock et al., 2003; Rajagopalan et al., 2002; Yuen et al., 2002; Satyamoorthy et al., 2003), we used two primer sets that amplified the two exons.”
BackgroundMethodInfluentialLuo, X.-J., Zhao, Q., Liu, J. S., Zheng, J., Qiu, M., Ju, H., & Xu, R. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.017 · Cited by 145
“Mutations in KRAS and BRAF seem to be mutually exclusive.(60,61) BRAF mutation was considered a prognosticator for poor survival in stage II/III CRC patients receiving adjuvant chemotherapy.”
BackgroundFrequent alterations of Ras signaling pathway genes in sporadic malignant melanomas
REIFENBERGER, J., Knobbe-Thomsen, C. B., Sterzinger, A. A., Blaschke, B., Schulte, K. W., Ruzicka, T., & Reifenberger, G. (2004) · International Journal of Cancer · doi:10.1002/ijc.11722 · Cited by 146
Toon, C. W., Walsh, M. D., Chou, A., Capper, D., Clarkson, A., Sioson, L., Clarke, S., Mead, S., Walters, R. J., Clendenning, M., et al. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31828f233d · Cited by 136
“Total, n (%) 98 (7) 183 (13) 93 (7) 1029 (73) Sex, n (%) Female 57 (58) 136 (74) 53 (57) 468 (46) Male 41 (42) 47 (26) 40 (43) 561 (55) Anatomic site, n (%) Cecum 20 (20) 50 (28) 33 (36) 182 (18) Ascending colon 31 (32) 64 (36) 25 (27) 110 (11) Transverse colon 16 (16) 40 (23) 21 (23) 71 (7) Descending colon 9 (9) 5 (…”
Lee, S., Cho, N., Choi, M., Yoo, E. J., Kim, J., & Kang, G. H. (2008) · Pathology International · doi:10.1111/j.1440-1827.2007.02197.x · Cited by 136
Lack of BRAF Mutation in Primary Uveal Melanoma
Cohen, Y., Goldenberg‐Cohen, N., Parrella, P., Chowers, I., Merbs, S. L., Pe’er, J., & Sidransky, D. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-1329 · Cited by 135
“Mutations in one of the RAF genes, BRAF, have been recently discovered in the majority of cutaneous melanomas,(15) cutaneous nevi,(19) and papillary thyroid carcinoma(20) and to a lesser extent in other cancers.(15,21) The predominant mutation reported in cutaneous melanoma and cutaneous nevi was a thymine-to-adenine…”
BackgroundThe molecular biology of esophageal adenocarcinoma
Koppert, L. B., Wijnhoven, B. P. L., van Dekken, H., Tilanus, H. W., & Dinjens, W. N. M. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20359 · Cited by 148
Duesberg, P., Fabarius, A., & Hehlmann, R. (2004) · IUBMB Life · doi:10.1080/15216540410001667902 · Cited by 135
Metabolism addiction in pancreatic cancer
Blum, R., & Kloog, Y. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.38 · Cited by 134
Mutations of the BRAF gene in squamous cell carcinoma of the head and neck
Weber, A., Langhanki, L., Sommerer, F., Markwarth, A., Wittekind, C., & Tannapfel, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206705 · Cited by 131
“In contrast to melanoma (Davies et al., 2002; Pollock et al., 2003) or colon cancer (Rajagopalan et al., 2002), we detected BRAF mutation only in a small number of HNSCC.”
Koinuma, K., Shitoh, K., Miyakura, Y., Furukawa, T., Yamashita, Y., Ota, J., Ohki, R., Choi, Y. L., Wada, T., Konishi, F., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.11523 · Cited by 134
Mutations and Response to Epidermal Growth Factor Receptor Inhibitors
Laurent-Puig, P., Lievre, A., & Blons, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0905 · Cited by 133
Molecular phenotypes of colorectal cancer and potential clinical applications
Kocarnik, J. M., Shiovitz, S., & Phipps, A. I. (2015) · Gastroenterology Report · doi:10.1093/gastro/gov046 · Cited by 132
“As part of the same pathway, BRAF and KRAS mutations tend to be mutually exclusive molecular events in CRC development [49].”
BackgroundConditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies
Mina, M., Raynaud, F., Tavernari, D., Battistello, E., Sungalee, S., Saghafinia, S., Laessle, T., Sanchez-Vega, F., Schultz, N., Oricchio, E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.010 · Cited by 129
“A prototypical example is the almost perfect mutual exclusivity between ERK-activating mutations affecting Ras genes and BRAF observed in multiple cancers (Rajagopalan et al., 2002).”
BackgroundChen, J.-H., Faquin, W. C., Lloyd, R. V., & Nosé, V. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.2 · Cited by 129
Review of Histopathological and Molecular Prognostic Features in Colorectal Cancer
Marzouk, O., & Schofield, J. B. (2011) · Cancers · doi:10.3390/cancers3022767 · Cited by 167
“BRAF and KRAS mutations tend to be mutually exclusive [208,209], the former being reported to be more associated with MSI than MSS tumors with subsequent abrogation of their favorable outcome [198].”
BackgroundOvarian serous carcinoma: recent concepts on its origin and carcinogenesis
Li, J., Fadare, O., Li, X., Kong, B., & Zheng, W. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-8 · Cited by 144
“It is of interest that mutations of these three genes are mutually exclusive [80,81].”
BackgroundAre KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Yokota, T. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012799014968 · Cited by 126
“None of the patients with CRC carried both KRAS and BRAF mutations, supporting the hypothesis that KRAS and BRAF mutations are mutually exclusive [51-53].”
ResultPrognostic implications of CpG island hypermethylator phenotype in colorectal cancers
Kim, J. H., Shin, S. H., Kwon, H. J., Cho, N., & Kang, G. H. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0857-0 · Cited by 134
“One series of studies suggested that BRAF mutation is closely associated with sporadic MSI+ CRCs [ 39 , 40], but this is disputed by recent studies indicating that BRAF mutation is closely associated with CIMP rather than MSI [16, 24].”
BackgroundBRAF mutations are detectable in conjunctival but not uveal melanomas
Spendlove, H. E., Damato, B. E., Humphreys, J., Barker, K. T., Hiscott, P. S., & Houlston, R. S. (2004) · Melanoma Research · doi:10.1097/00008390-200412000-00003 · Cited by 129
Cajuso, T., Hänninen, U. A., Kondelin, J., Gylfe, A. E., Tanskanen, T., Katainen, R., Pitkänen, E., Ristolainen, H., Kaasinen, E., Taipale, M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28705 · Cited by 125
“in MSI CRC have been identified, the best characterized being the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E with mutation frequency of nearly 30%.(4,5) With next-generation sequencing methods, however, it is now possible to perform more comprehensive mutation profiling of these tumors.”
BackgroundEGFR and KRAS in Colorectal Cancer
Markman, B., Ramos, F. J., Capdevila, J., & Tabernero, J. M. (2010) · Advances in clinical chemistry · doi:10.1016/s0065-2423(10)51004-7 · Cited by 147
Serrated Colon Polyps as Precursors to Colorectal Cancer
Sweetser, S. R., Smyrk, T. C., & Sinicrope, F. A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.12.004 · Cited by 124
Back to the roots: the remarkable RAF oncogene story
Zebisch, A., & Troppmair, J. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6005-y · Cited by 136
Soares, P., Trovisco, V., Rocha, A. S., Feij�o, T., Rebocho, A. P., Fonseca, E., de Castro, I. V., Cameselle‐Teijeiro, J., Cardoso-Oliveira, M., & Sobrinho-Sim�es, M. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-004-1018-0 · Cited by 124
“[25]. This genetic alteration, like the V599E, corresponds with the activation segment of the BRAF gene (exon 15); it had been previously detected in a few cases of melanoma and colorectal carcinoma [2, 15 ] and, by our group, in a follicular adenoma of the thyroid [22].”
BackgroundSforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123
Expression and genomic profiling of colorectal cancer
Cardoso, J., Boer, J. M., Morreau, H. M., & Fodde, R. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.004 · Cited by 141
Seto, M., Ohta, M., Asaoka, Y., Ikenoue, T., Tada, M., Miyabayashi, K., Mohri, D., Tanaka, Y., Ijichi, H., Tateishi, K., et al. (2009) · Molecular Carcinogenesis · doi:10.1002/mc.20516 · Cited by 127
“Pancreatic cancer has a high incidence of activating KRAS mutations, and colon cancer is also reported to have mutations of BRAF and KRAS [16,17].”
BackgroundPohl, G., Ho, C.-L., Kurman, R. J., Bristow, R., Wang, T.-L., & Shih, I.-M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3625 · Cited by 123
“Furthermore, we found that mutations in BRAF at codon 599 and KRAS at codons 12 and 13 were mutually exclusive (2, 5), a finding consistent with the data in melanoma and colorectal carcinoma (6, 7).”
Molinari, F., Martin, V, Saletti, P., De Dosso, S., Spitale, A., Camponovo, A., Bordoni, A., Crippa, S., Mazzucchelli, L., & Frattini, M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604848 · Cited by 122
“First, we confirm that K-Ras and BRAF mutations are mutually exclusive (Rajagopalan et al, 2002).”
BackgroundResultOddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0396 · Cited by 121
“These preclinical studies have provided the rationale for testing dual/triple vertical blockade of the MAPK pathway by targeting EGFR, BRAF, and MEK in BRAF -mutant mCRC patients.”
InfluentialSelf-citationTargeting the Mitogen-Activated Protein Kinase Pathway in the Treatment of Malignant Melanoma
Panka, D. J., Atkins, M. B., & Mier, J. W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2539 · Cited by 120
“For example, f60% of cutaneous melanomas have an activating mutation in the catalytic domain of the serine-threonine kinase B-raf (2, 3).”
BackgroundInfluentialBRAF gene: From human cancers to developmental syndromes
Hussain, M. R. M., Baig, M., Mohamoud, H. S. A., Ul‐Haq, Z., Hoessli, D. C., Khogeer, G. S., Al-Sayed, R. R., & Al-Aama, J. Y. (2014) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2014.10.002 · Cited by 127
“Additionally, the accumulation of several genetic alterations, such as T1796A (V599E), G1382T (R461I), T1385G (I462S), G1388A (G463E) and A1798G (K600E), are more commonly found in larger adenomas (<1 cm across) than in smaller adenomas (Rajagopalan et al., 2002).”
BackgroundInfluentialChemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
Bagnyukova, T. V., Serebriiskii, I. G., Zhou, Y., Hopper-Borge, E. A., Golemis, E. A., & Astsaturov, I. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.9.13738 · Cited by 118
Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer
Gridelli, C., Maione, P., Gaizo, F. D., Colantuoni, G., Guerriero, C., Ferrara, C., Nicolella, D., Comunale, D., Vita, A. D., & Rossi, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-2-191 · Cited by 128
“B-RAF is reportedly mutated in 70% of malignant melanomas [21], in 33% of papillary thyroid carcinomas [22], and in lower frequencies in other cancers [ 23 ].”
BackgroundOncogenic mutations as predictive factors in colorectal cancer
Lièvre, A., Blons, H., & Laurent-Puig, P. (2010) · Oncogene · doi:10.1038/onc.2010.89 · Cited by 117
“It is important to note that BRAF and KRAS mutations are mutually exclusive (Rajagopalan et al., 2002; Barault et al., 2008b).”
BackgroundGenomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines
Melnikova, V. O., Bolshakov, S. V., Walker, C., & Ananthaswamy, H. N. (2004) · Oncogene · doi:10.1038/sj.onc.1207405 · Cited by 132
“…$25.00 www.nature.com/onc in 66% of primary sporadic human melanomas, and at lower rate in other cancers (Brose et al., 2002; Davies et al., 2002; Rajagopalan et al., 2002; Cohen et al., 2003; Dong et al., 2003; Gorden et al., 2003; Pollock et al., 2003; Weber et al., 2003; Xu et al., 2003).”
BackgroundInfluentialAmeloblastoma: A Review of Recent Molecular Pathogenetic Discoveries
Brown, N. A., & Betz, B. L. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s29329 · Cited by 149
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer
Chan, D. L. H., Segelov, E., Wong, R. S., Smith, A., Herbertson, R. A., Li, B. T., Tebbutt, N., Price, T., & Pavlakis, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007047.pub2 · Cited by 114
Oncogenic KRAS and BRAF Differentially Regulate Hypoxia-Inducible Factor-1α and -2α in Colon Cancer
Kikuchi, H., Pino, M. S., Zeng, M., Shirasawa, S., & Chung, D. C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2213 · Cited by 116
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer
Sinicrope, F. A., Okamoto, K., Kasi, P. M., & Kawakami, H. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.02.008 · Cited by 116
Anoikis resistance––protagonists of breast cancer cells survive and metastasize after ECM detachment
Dai, Y., Zhang, X., Ou, Y., Zou, L., Zhang, D., Yang, Q., Qin, Y., Du, X., Li, W., Yuan, Z., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01183-4 · Cited by 137
Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma
Kim, S. Y., Kim, S., Hahn, H. J., Lee, Y. W., Choe, Y. B., & Ahn, K. J. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.02.1113 · Cited by 126
Important molecular genetic markers of colorectal cancer
Kudryavtseva, A. V., Lipatova, A. V., Zaretsky, A. R., Moskalev, A. A., Fedorova, M. S., Rasskazova, A. S., Shibukhova, G. A., Snezhkina, A. V., Kaprin, A. D., Alekseev, B. Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9796 · Cited by 114
“BRAF mutations are rarely found in MSS or MSI-L tumors, which are characterized by poor prognosis [139, 161-163].”
BackgroundWeber, A., Hengge, U. R., Urbanik, D., Markwart, A., Mirmohammadsaegh, A., Reichel, M. B., Wittekind, C., Wiedemann, P., & Tannapfel, A. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000101732.89463.29 · Cited by 112
“The high frequency of BRAF activation mutations in cutaneous melanomas and also melanocytic nevi provide new evidence that the Ras-RAF-MEK-Erk pathway plays a critical role in tumorigenesis of melanomas (Rajagopalan et al, 2002).”
BackgroundThe heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
Fanelli, G. N., Pozzo, C. A. D., Depetris, I., Schirripa, M., Brignola, S., Biason, P., Balistreri, M., Santo, L. D., Lonardi, S., Munari, G., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1117-2 · Cited by 129
Saridaki, Z., Papadatos-Pastos, D., Tzardi, M. N., Mavroudis, D., Bairaktari, E. T., Arvanity, H., Stathopoulos, E. N., Georgoulias, V., & Souglakos, J. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605694 · Cited by 117
“001), in agreement with the published evidence (Rajagopalan et al, 2002; Oliveira et al, 2003; Wang et al, 2003).”
BackgroundResultNoonan, Costello and cardio–facio–cutaneous syndromes: dysregulation of the Ras–MAPK pathway
Tidyman, W. E., & Rauen, K. A. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000902 · Cited by 110
Molecular Dissection of Microsatellite Instable Colorectal Cancer
Vilar, E., & Tabernero, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0471 · Cited by 111
Tougeron, D., Lecomte, T., Pagès, J., Villalva, C., Collin, C., Ferru, A., Tourani, J. M., Silvain, C., Levillain, P., & Karayan, L. (2013) · Annals of Oncology · doi:10.1093/annonc/mds620 · Cited by 132
“KRAS and BRAF mutations were considered to be mutually exclusive [28].”
BackgroundRegulation of Raf through Phosphorylation and N Terminus-C Terminus Interaction
Chong, H., & Guan, K.-L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212803200 · Cited by 109
Oikonomou, E., Koustas, E., Goulielmaki, M., & Pintzas, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2555 · Cited by 131
“In Cancer models: The identification of mutationally activated KRAS and BRAF alleles in several tumour models supports the importance of this signalling pathway in cancer progression [27, 33].”
BackgroundMao, C., Wu, X.-Y., Yang, Z.-Y., Threapleton, D. E., Yuan, J.-Q., Yu, Y.-Y., & Tang, J.-L. (2015) · Scientific Reports · doi:10.1038/srep08065 · Cited by 107
KRAS Mutation Testing in Colorectal Cancer
Plesec, T. P., & Hunt, J. L. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181a9d4ed · Cited by 115
Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 145
“BRAF mutations are common in melanoma (50%) (68), thyroid papillary cancers (approximately 35%) (69), and colorectal cancers (5%–10%) (70).”
BackgroundMiyamoto, Y., Suyama, K., & Baba, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040752 · Cited by 106
“In addition, BRAF mutations are mutually exclusive with RAS mutations [81].”
BackgroundPresent and future of metastatic colorectal cancer treatment: A review of new candidate targets
Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Sforza, V., Ciardiello, D., Napolitano, S., Corte, C. M. D., Morgillo, F., Raucci, A., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i26.4675 · Cited by 115
Schneider, M. A., Eden, J., Pache, B. C.-E., Laminger, F., López‐López, V., Steffen, T., Hübner, M., Kober, F., Roka, R., Campos, P. C., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002899 · Cited by 111
Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF
Cisowski, J., Sayin, V. I., Liu, M., Karlsson, C., & Bergo, M. O. (2016) · Oncogene · doi:10.1038/onc.2015.186 · Cited by 104
Suzuki, H., Igarashi, S., Nojima, M., Maruyama, R., Yamamoto, E., Kai, M., Akashi, H., Watanabe, Y., Yamamoto, H., Sasaki, Y., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp179 · Cited by 104
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF
Zheng, G., Tseng, L.-H., Chen, G., Haley, L., Illei, P., Gocke, C. D., Eshleman, J. R., & Lin, M.-T. (2015) · BMC Cancer · doi:10.1186/s12885-015-1811-y · Cited by 103
“The BRAF gene is mutated in approximately 7 % of human cancers overall [8], specifically, 40 % to 60 % of malignant melanomas [9], 10 % to 15 % of colorectal cancers (CRCs) [10], and 1 to 5 % of non-small cell lung cancers (NSCLC) [11, 12].”
BackgroundLi, Z.-N., Zhao, L., Yu, L.-F., & Wei, M.-J. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa022 · Cited by 104
“In addition, some studies report that the BRAF mutation and the RAS mutation are mutually exclusive in mCRC [29, 53, 54].”
BackgroundKawada, K., Nakamoto, Y., Kawada, M., Hida, K., Matsumoto, T., Murakami, T., Hasegawa, S., Togashi, K., & Sakai, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1909 · Cited by 104
“All patients with mutated KRAS tumors had wild-type BRAF tumors, consistent with results of previous studies which indicate that KRAS and BRAF mutations occur in a mutually exclusive pattern (11, 12, 15).”
Molecular Alterations and Biomarkers in Colorectal Cancer
Grady, W. M., & Pritchard, C. C. (2014) · Toxicologic Pathology · doi:10.1177/0192623313505155 · Cited by 104
“As discussed above, BRAF mutations are much more frequent in MSI tumors (*35%) compared to MSS tumors (*5%) and are very tightly linked to CIMP cancers and the serrated neoplasia pathway (Lubomierski et al. 2005; Rajagopalan et al. 2002).”
BackgroundEffect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
Lee, J., Lee, I., Han, B., Park, J. O., Jang, J., Park, C., & Kang, W. K. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr070 · Cited by 103
Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity
Tan, H., Bao, J., & Zhou, X. (2015) · Scientific Reports · doi:10.1038/srep12566 · Cited by 109
“For example, KRAS and BRAF gene mutations exclusively exist in colorectal cancers 44 , whereas EGFR mutations rarely co-occurred with KRAS in any cancer type 45 .”
Epigenetic-Genetic Interactions in theAPC/WNT, RAS/RAF, andP53Pathways in Colorectal Carcinoma
Suehiro, Y., Wong, C. W., Chirieac, L. R., Kondo, Y., Shen, L., Webb, C. R., Chan, Y. W., Chan, A. S. Y., Chan, T. L., Wu, T., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1802 · Cited by 105
KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy
Gaedcke, J., Grade, M., Jung, K., Schirmer, M., Jo, P., Obermeyer, C., Wolff, H. A., Herrmann, M. K. A., Beißbarth, T., Becker, H., et al. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.10.001 · Cited by 110
“To some extent BRAF mutations and KRAS mutations can be considered as equivalent in their tumorigenic effect [9,10], and at least the T1799A transversion seems to be inversely correlated with the frequency of KRAS mutations [7,9,11].”
Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review)
Νikolouzakis, Τ. Κ., Vassilopoulou, L., Fragkiadaki, P., Sapsakos, T. M., Papadakis, G., Spandidos, D. A., Tsatsakis, A. M., & Tsiaoussis, J. (2018) · Oncology Reports · doi:10.3892/or.2018.6330 · Cited by 136
Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer
Kim, J. H., & Kang, G. H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4230 · Cited by 113
Pichler, M., Balić, M., Stadelmeyer, E., Ausch, C., Wild, M., Guelly, C., Bauernhofer, T., Samonigg, H., Höefler, G., & Dandachi, N. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080100 · Cited by 107
“Also, the comparison of our result with previously published reports is limited due to the heterogeneity of cohorts and methodological differences.(1,33) Based on our long-term experience, microsatellite instability is present in less than 10% of regionally diagnosed colorectal cancers (unpublished data).”
ResultGagnière, J., Dupré, A., Gholami, S., Pezet, D., Boerner, T., Gönen, M., Kingham, T. P., Allen, P. J., Balachandran, V. P., DeMatteo, R. P., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002968 · Cited by 107
Relationship between genetic alterations and prognosis in sporadic colorectal cancer
Chang, S., Lin, J.-K., Yang, S. H., Wang, H., Li, A. F., & Chi, C. (2005) · International Journal of Cancer · doi:10.1002/ijc.21563 · Cited by 101
“Recent report showed that activating mutations in BRAF, a member of RAF gene family which encode kinases that are regulated by Ras and mediate cellular responses to growth signals, was found to be associated with MSI-H cancers.(18)”
BackgroundActivated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation
Domingo, E., Espín, E., Armengol, M., Oliveíra, C., Pinto, M., Duval, A., Louis‐Brennetot, C., Seruca, R., Hamelin, R., Yamamoto, H., et al. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10310 · Cited by 100
“Recently, a high incidence of activating mutations in exon 15 of BRAF, a member of the RAF family of kinases that acts upstream of MEK1/2 kinases in response to RAS signals, has been detected in colorectal tumors (Davies et al., 2002; Rajagopalan et al., 2002; Yuen et al., 2002).”
BackgroundResultInfluentialSomatic Mutations of PPP2R1A in Ovarian and Uterine Carcinomas
Shih, I., Panuganti, P. K., Kuo, K., Mao, T., Kuhn, E., Jones, S., Velculescu, V. E., Kurman, R. J., & Wang, T. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.01.009 · Cited by 107
Self-citationCurrent and future biomarkers in colorectal cancer
Zarkavelis, G., Boussios, S., Papadaki, A., Katsanos, K. H., Christodoulou, D. K., & Pentheroudakis, G. (2017) · Annals of Gastroenterology · doi:10.20524/aog.2017.0191 · Cited by 119
“This point mutation is mutually exclusive with KRAS mutations and is an adverse prognostic marker in advanced disease [31,32].”
BackgroundMSH6 and MUTYH Deficiency Is a Frequent Event in Early-Onset Colorectal Cancer
Giraldez, M. D., Balaguer, F., Bujanda, L., Cuatrecasas, M., Muñoz, J., Alonso‐Espinaco, V., Larzábal, M., Petit, A., Gonzalo, V., Ocaña, T., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1491 · Cited by 102
Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas
Edmunds, S., Cree, I. A., Nicolantonio, F. D., Hungerford, J. L., Hurren, J., & Kelsell, D. P. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600919 · Cited by 97
“A smaller number of mutations were also found in a region of exon 11, and other lower levels of mutations have been reported in these codons in cancers including ovarian, sarcomas, lung (Brose et al, 2002), and colorectal tumours (Rajagopalan et al, 2002).”
BackgroundReal-time allele-specific amplification for sensitive detection of the BRAF mutation V600E
Jarry, A., Masson, D., Cassagnau, E., Parois, S., LABOISSE, C. L., & Denis, M. G. (2004) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2004.05.004 · Cited by 97
Metadata
- Authors
- Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E.
- Affiliations
- Johns Hopkins University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2002-08-29
- Volume
- 418
- Issue
- 6901
- Pages
- 934-934
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985035689
- Cited by
- 1,224
- References
- 8
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 29 · 2023: 30 · 2022: 26 · 2021: 42 · 2020: 38 · 2019: 35 · 2018: 41 · 2017: 42 · 2016: 51 · 2015: 76 · 2014: 65 · 2013: 74 · 2012: 78
- FWCI
- 37.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- BRAF mutation, KRAS mutation, oncogenic Ras, DNA mismatch repair, colorectal cancer, melanoma, carcinogenesis, DNA repair, mutation spectrum, growth factor signaling
- MeSH terms
- DNA Damage, DNA Repair, Gene Frequency, Humans, Mutation, Oncogenes, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins c-raf, Base Pair Mismatch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.